文献速递脊柱关节炎

司库奇尤单抗对银屑病关节炎患者滑膜炎和附着点炎的影响:随机双盲ULTIMATE试验及其开放标签扩展的52周临床与超声结果

Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension.
PubMed 文献 · Semin Arthritis Rheum · 2023-08-19

ULTIMATE研究纳入166例生物制剂初治的银屑病关节炎患者,随机接受司库奇尤单抗或安慰剂治疗12周,随后开放标签至52周。司库奇尤单抗组第12周GLOESS滑膜炎评分和SPARCC附着点炎指数较安慰剂显著降低,并维持至52周;安慰剂转司库奇尤单抗组第24周达到相似改善。各关键领域临床应答持续改善,未发现新的安全性信号。

要点

  • 司库奇尤单抗组第12周GLOESS滑膜炎评分较安慰剂显著降低,并稳定维持至第52周。
  • 司库奇尤单抗组第12周SPARCC附着点炎指数较安慰剂显著降低,持续改善至第52周。
  • 安慰剂转司库奇尤单抗组第24周滑膜炎改善程度与司库奇尤单抗组相似,此后保持稳定。

核心结论

  • ULTIMATE研究显示,司库奇尤单抗治疗银屑病关节炎患者至第52周,临床和超声评估的滑膜炎与附着点炎持续改善,临床疗效持续,未发现新的或意外的安全性信号。

研究设计与样本

  • 随机、安慰剂对照、3期研究(ULTIMATE)纳入166例生物制剂初治、对传统合成改善病情抗风湿药应答不足、伴活动性PDUS滑膜炎和临床附着点炎的银屑病关节炎患者。
  • 研究分3个治疗期:第1期(基线至第12周)随机接受皮下司库奇尤单抗(根据皮肤银屑病严重程度选择150 mg或300 mg)或安慰剂,每周一次至第4周,之后每4周一次至第12周。
  • 第2期(第12–24周)所有患者接受开放标签司库奇尤单抗,安慰剂组转为司库奇尤单抗(150 mg或300 mg)。
  • 第3期(第24–52周)为延长开放标签治疗期。

主要发现

  • 166例入组患者中144例完成第52周。
  • 第12周时,司库奇尤单抗组GLOESS滑膜炎评分较安慰剂组显著降低,此后司库奇尤单抗组滑膜炎稳定改善至第52周;安慰剂转司库奇尤单抗组自第12周起至第24周达到相似改善水平,此后保持稳定。
  • 第12周时,司库奇尤单抗组SPARCC附着点炎指数较安慰剂组显著降低,并持续改善至第52周。
  • 前两个治疗期内,司库奇尤单抗组全球OMERACT PDUS附着点炎评分在数值上低于安慰剂转司库奇尤单抗组,第三治疗期两组均有一定稳定性。
  • 两个治疗组至第52周在所有银屑病关节炎关键领域均观察到临床应答改善,未发现新的或意外的安全性信号。

关键数值与推荐

  • 第12周司库奇尤单抗组GLOESS滑膜炎评分较安慰剂组显著降低。
  • 第12周司库奇尤单抗组SPARCC附着点炎指数较安慰剂组显著降低。
  • 前两个治疗期司库奇尤单抗组全球OMERACT PDUS附着点炎评分在数值上低于安慰剂转司库奇尤单抗组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In the ULTIMATE study with an open label extension, we assessed the long-term effect of secukinumab at tissue level on synovitis and enthesitis, and across all psoriatic arthritis (PsA) manifestations, using both clinical evaluations and power Doppler ultrasonography (PDUS). METHODS: This randomised, placebo-controlled, Phase 3 study (ULTIMATE) included biologic-naïve patients with PsA with active PDUS synovitis and clinical enthesitis, and inadequate response to conventional synthetic disease-modifying antirheumatic drugs. The study consisted of 3 treatment periods; in the first period (baseline to week 12) patients were randomised to receive subcutaneous secukinumab (150 mg or 300 mg according to severity of skin psoriasis) or placebo every week until week 4 and once every 4 weeks up to week 12. In the second period (weeks 12-24) all patients received open-label secukinumab with placebo patients switching to secukinumab (150 mg or 300 mg). The third period (weeks 24-52) was an extended open-label treatment period. The long-term responsiveness of the Global EULAR-OMERACT Synovitis Score (GLOESS), clinical enthesitis and global PDUS-detected enthesitis score (using two candidate definitions of activity) at patient level, together with clinical efficacy across key manifestations of PsA and safety were assessed. RESULTS: Of the 166 patients enrolled, 144 completed week 52. A significant reduction in GLOESS was demonstrated in the secukinumab group vs placebo at week 12, followed by a stable reduction of synovitis until week 52 in the secukinumab group while placebo switchers from week 12 reached a similar level of reduction at week 24 with stability thereafter. Likewise, a significant reduction in the Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index was shown in the secukinumab group vs placebo at week 12 with sustained improvement to week 52. Global OMERACT PDUS enthesitis scores were numerically lower in secukinumab vs placebo switchers in the first two treatment periods, with some stability in the third period in both groups. Improvements in clinical responses were also observed across all key domains of PsA up to week 52 in both treatment groups with no new or unexpected safety signals. CONCLUSIONS: ULTIMATE showed consistent improvements in clinically and ultrasound-assessed synovitis and enthesitis and sustained clinical efficacy through week 52 in patients with PsA treated with secukinumab and placebo switched to secukinumab.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. D'Agostino MA, Carron P, Gaillez C, et al. Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension. Semin Arthritis Rheum. 2023. PMID: 37660536. doi:10.1016/j.semarthrit.2023.152259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。